Investments, Funding & Disinvestment

Imperative Care reports that medical professionals have used its products commercially in more than 78,000 procedures, demonstrating significant market adoption and clinical trust.

This deal builds on the existing partnership between the two companies and could expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets.

The merger is set to complete within the next quarter, pending final regulatory and statutory approvals from the National Company Law Tribunal (NCLT).

Radiologists at the Center now access more than 60 AI services, enabling detection of pathologies across 43 clinical areas.

The platform serves multiple surgical disciplines, including arthroscopy, bariatric surgery, general surgery, gynecology, hepatopancreatobiliary transplant procedures, thoracic surgery, and urology.

LYOCONTRACT has partnered with Syntegon, a leading equipment supplier, to install a complete filling and lyophilization line at the new facility.

The site can produce up to 40 CGMP batches annually, supporting parallel processing for multiple client programs and ensuring reliable supply chains.

The facility will house sophisticated equipment, including liquid-phase peptide synthesis reactors ranging from 250 to 3,000 liters and solid-phase peptide synthesis reactors up to 500 liters.

This latest commitment builds on a previous 7 billion yen (USD44 million) investment between 2022 and 2025, which funded automated device-sorting machines, enhancements to the quality testing lab, a new factory building, and an additional packaging line.

The management has allocated the funds specifically to address critical equipment shortages that currently limit the hospital’s service delivery capacity.